Kidney cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 6, 2012, Pages 948-951

  Linehan, W Marston ^a   Rathmell, W Kimryn ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Kidney cancer; Renal cancer

Indexed keywords

AXITINIB; BEVACIZUMAB; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; FUMARATE HYDRATASE; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IPILIMUMAB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; PAZOPANIB; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; SCATTER FACTOR RECEPTOR; SORAFENIB; SUCCINATE DEHYDROGENASE; SUCCINATE DEHYDROGENASE B; SUCCINATE DEHYDROGENASE D; SUNITINIB; TIVOZANIB; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

CHROMATIN ASSEMBLY AND DISASSEMBLY; CITRIC ACID CYCLE; DISEASE ASSOCIATION; DISEASE COURSE; ELECTRON TRANSPORT; GENETIC TRANSCRIPTION; HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CARCINOMA; HISTONE MODIFICATION; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY METASTASIS; LEIOMYOMATOSIS; MELANOMA; METABOLIC DISORDER; MUTATION; NEPHRECTOMY; PBRM1 GENE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SETD2 GENE; TUMOR GENE;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS;

EID: 84870541239     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.08.021     Document Type: Review

References (25)

1. Linehan W.M., Walther M.M., Zbar B. The genetic basis of cancer of the kidney. J Urol 2003, 170:2163-2172.
2. Linehan W.M., Srinivasan R., Schmidt L.S. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 2010, 7:277-285.
3. Isaacs J.S., Jung Y.J., Mole D.R., et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability. Cancer Cell 2005, 8:143-153.
4. Tong W.H., Sourbier C., Kovtunovych G., et al. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases metabolic propensities and lowers cellular iron levels. Cancer Cell 2011, 20:315-327.
5. Mullen A.R., Wheaton W.W., Jin E.S., et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature. On Line 2011, in press.
6. Ricketts C., Woodward E.R., Killick P., et al. Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst 2008, 100:1260-1262.
7. Yang Y., Valera V.A., Padilla-Nash H.M., et al. UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: In vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet Cytogenet 2010, 196:45-55.
8. Liu J., Ghanim M., Xue L., et al. Analysis of Drosophila segmentation network identifies a JNK pathway factor overexpressed in kidney cancer. Science 2009, 323:1218-1222.
9. Dalgliesh G.L., Furge K., Greenman C., et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010, 463:360-363.
10. Varela I., Tarpey P., Raine K., Chan-on W., Subimerb C., Dykema K., Furge K., Campbell P.J., et al. Stratton: the BT MR, Futreal PA. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011, 469:539-542.
11. Kenneth N.S., Mudie S., van U.P., et al. SWI/SNF regulates the cellular response to hypoxia. J Biol Chem 2009, 284:4123-4131.
12. van P.H., Becker F., Cadeddu J.A., Gill I.S., Janetschek G., Jewett M.A., Laguna M.P., Marberger M., Montorsi F., Polascik T.J., Ukimura O., Zhu G. Treatment of localised renal cell carcinoma. Eur Urol 2011, 60:662-672.
13. van P.H., Da P.L., Albrecht W., Matveev V., Bono A., Borkowski A., Colombel M., Klotz L., Skinner E., Keane T., Marreaud S., Collette S., Sylvester R. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2011, 59:543-552.
14. Yang J.C., Hughes M., Kammula U., et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007, 30:825-830.
15. Sznol M., Powderly J.D., Smith D.C., et al. Safety and antitumor activity of biweekly MDX-1106 (anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. J Clin Oncol 2010, 28(Suppl). Abstr:2506.
16. Jonasch E., Bair A., Chen Y., et al. Axitinib with or without dose titration as first-line therapy for metastatic renal cell carcinoma (mRCC). J Clin Oncol 2010, 28(Suppl). Abstr TPS235.
17. Motzer R.J., Bhargava P., Esteves B., et al. A phase III, randomized, controlled study to compare tivozanib with sorafenib in patients (pts) with advanced renal cell carcinoma (RCC). J Clin Oncol 2011, 29(Suppl 7):310-315. Abstr:310-5.
18. Rini B.I., Escudier B., Tomczak P., et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet 2011, 378:1931-1939.
19. Nosov D., Bhargava P., Esteves W.B., et al. Final analysis of the phase II randomized discontinuation trial (RDT) of tivozanib (AV-951) versus placebo in patients with renal cell carcinoma (RCC). J Clin Oncol 2011, 29(Suppl). Abstr:4550.
20. Huang D., Ding Y., Zhou M., et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010, 70:1063-1071.
21. Herbst R.S., Hong D., Chap L., et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009, 27:3557-3565.
22. Shen C., Beroukhim R., Schumacher S.E., et al. Genetic and functional studies implicate HIF1a as a 14q kidney cancer suppressor gene. Cancer Res 2011, 22335.
23. Cho D.C., Cohen M.B., Panka D.J., et al. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 2010, 16:3628-3638.
24. Zimmer M., Ebert B.L., Neil C., et al. Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing. Mol Cell 2008, 32:838-848.
25. Peruzzi B., Athauda G., Bottaro D.P. The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells. Proc Natl Acad Sci U S A 2006, 103:14531-14536.